Biological
BVS857
BVS857 is a biological therapy with 3 clinical trials. Historical success rate of 66.7%.
Total Trials
3
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
66.7%
Based on 2 completed trials
Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
100%(2 trials)
Terminated
1(33%)
Phase Distribution
Ph phase_1
1
33%
Ph phase_2
2
67%
Phase Distribution
1
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
2(66.7%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
66.7%
2 of 3 finished
Non-Completion Rate
33.3%
1 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(2)
Terminated(1)
Detailed Status
Completed2
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
66.7%
Most Advanced
Phase 2
Trials by Phase
Phase 11 (33.3%)
Phase 22 (66.7%)
Trials by Status
terminated133%
completed267%
Recent Activity
0 active trials
Showing 3 of 3
completedphase_2
Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy
NCT02024932
terminatedphase_2
Study of Tolerability and Efficacy of BVS857 in Severe Burn Subjects
NCT02074995
completedphase_1
Safety and Tolerability of BVS857 in Subjects With Insulin Resistance
NCT01435330
Clinical Trials (3)
Showing 3 of 3 trials
NCT02024932Phase 2
Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy
NCT02074995Phase 2
Study of Tolerability and Efficacy of BVS857 in Severe Burn Subjects
NCT01435330Phase 1
Safety and Tolerability of BVS857 in Subjects With Insulin Resistance
All 3 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 3